New Research Finds Direct-to-Consumer (DTC) Pharmaceutical Advertising Costs U.S. Taxpayers Billions of Dollars

As reported in Politico, a new analysis by CSRxP finds that limiting or taxing DTC ads could increase federal revenue by up to $1.8 billion annually. The analysis is based on the potential tax impact if advertising expenses were not tax-deductible as they are today. The research found that 10 of the largest pharmaceutical manufacturers spent nearly $14 billion on DTC advertising in 2023 alone, resulting in a loss of $1 billion each year in federal tax revenue.

Only two countries in the world allow DTC pharmaceutical ads, the U.S. and New Zealand. As noted in the report, critics argue that DTC advertising “encourages inappropriate prescribing, contributes to rising health care expenditures, weakens doctor-patient relationships, and can keep patients from making fully informed decisions.” HHS Secretary Robert F. Kennedy Jr. has publicly said tv drug ads should be banned and lawmakers have considered eliminating the tax deduction in the past. CSRxP Executive Director Lauren Aronson notes, “The findings of this study should add to the bipartisan momentum in Washington to bring greater scrutiny to the pharmaceutical industry’s aggressive marketing practices in the U.S., their impact on drug prices, and solutions to discourage or tax Big Pharma’s DTC advertising.”

CSRxP Executive Director Lauren Aronson notes, “The findings of this study should add to the bipartisan momentum in Washington to bring greater scrutiny to the pharmaceutical industry’s aggressive marketing practices in the U.S., their impact on drug prices, and solutions to discourage or tax Big Pharma’s DTC advertising.”